Topic: Lynparza Approved To Treat High-Risk, Early-Stage, HER2-, BRCA+

Forum: Triple-Negative Breast Cancer — Share with others who have ER-/PR-/HER2- breast cancer.

Posted on: May 10, 2022 03:54PM

Posted on: May 10, 2022 03:54PM

moderators wrote:

Lynparza Approved To Treat High-Risk, Early-Stage, HER2-Negative Breast Cancer With BRCA Mutation
Mar 13, 2022

The FDA approved Lynparza to treat early-stage, HER2-negative breast cancer with a BRCA1 or BRCA2 mutation and a high risk of recurrence, which also has been previously treated with chemotherapy — either before or after surgery. Read more...

To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply
Scroll to top button